Is routine screening for Candida auris necessary in ICU?
- PMID: 39534293
- PMCID: PMC11551662
- DOI: 10.18502/ijm.v16i5.16807
Is routine screening for Candida auris necessary in ICU?
Abstract
Background and objectives: The capability to cause invasive infection, multi-drug resistance, and health care-associated outbreaks of Candida auris have made it a pathogen of great concern. Estimating how many patients in our intensive care unit had C. auris colonization and what characteristics put patients at risk for having Candida spp. colonization were the primary goals of the study.
Materials and methods: Swabs from axilla and groin were collected from 229 patients getting admitted to the ICU. Samples were inoculated into CHROMagarTM Candida Plus medium. Colonies presumptively identified as C. auris by the presence of light blue with blue halo and were confirmed by VITEK-2.
Results: Our study showed that only one patient was colonized with C. auris. A total of 47 (20.5%) patients were colonized with Candida spp., of which Candida parapislosis was the predominant organism. History of antibiotic use and cerebrovascular accident were independent risk factors in Candida colonization.
Conclusion: Active screening for Candida auris in all patients is not required in our hospital as the prevalence was very low and not cost-effective. Therefore we plan to modify our screening strategy and use risk factors based surveillance strategy as it may serve as an ideal strategy.
Keywords: Candida; Colonization; Infection; Resistant; Screening.
Copyright© 2024 The Authors. Published by Tehran University of Medical Sciences.
Figures
Similar articles
-
Novel Chromogenic Medium CHROMagarTM Candida Plus for Detection of Candida auris and Other Candida Species from Surveillance and Environmental Samples: A Multicenter Study.J Fungi (Basel). 2022 Mar 9;8(3):281. doi: 10.3390/jof8030281. J Fungi (Basel). 2022. PMID: 35330283 Free PMC article.
-
Enhancing ICU Candida spp. surveillance: a cost-effective approach focused on Candida auris detection.Front Cell Infect Microbiol. 2024 Nov 1;14:1463456. doi: 10.3389/fcimb.2024.1463456. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39554808 Free PMC article.
-
CHROMagarTM Candida Plus: A novel chromogenic agar that permits the rapid identification of Candida auris.Med Mycol. 2021 Mar 4;59(3):253-258. doi: 10.1093/mmy/myaa049. Med Mycol. 2021. PMID: 32525988
-
Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases.Intern Med J. 2019 Oct;49(10):1229-1243. doi: 10.1111/imj.14612. Intern Med J. 2019. PMID: 31424595 Review.
-
Candida auris: An emerging drug resistant yeast - A mini-review.J Mycol Med. 2018 Sep;28(3):568-573. doi: 10.1016/j.mycmed.2018.06.007. Epub 2018 Jul 17. J Mycol Med. 2018. PMID: 30030072 Review.
References
-
- Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus-United States, May 2013–August 2016. Am J Transplant 2017; 17: 296–299. - PubMed
-
- Harris E. CDC: Candida auris fungal infections and drug resistance on the rise. JAMA 2023; 329: 1248. - PubMed
-
- Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 2009; 53: 41–44. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous